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Abstract
Transsphenoidal surgery provides a minimal invasive treatment for pituitary adenoma. Our aim is to evaluate the endo-
crinological outcomes after adenoma resection focusing on the corticotroph function, and to identify prognostic factors for 
an impaired hypothalamic–pituitary–adrenal-axis function (HPA) and the reliability of postoperative early morning serum 
cortisol measurements. We performed a retrospective analysis of all patients treated for pituitary adenoma from April 
2006 to January 2019 in our neurosurgical department. Pituitary function was assessed pre- and postoperatively as well as 
at 6 weeks to 12 weeks and at 1-year follow-up. Two hundred eleven patients were included. Nine percent of the patients 
recovered from a preoperative adrenal insufficiency, 10.4% developed a new need for hormone substitution, and a long-term 
deficiency of the hypothalamic–pituitary–adrenal-axis was observed in 30.9%. Cortisol measurements 5 days after surgery 
had a lower area under the curve (AUC) than cortisol levels detected after 6 to 12 weeks (AUC 0.740 vs. AUC 0.808) in 
predicting an intact corticotrope function. The cut-off value determined for cortisol measured after 6 weeks was 6.95 µg/dl 
(sensitivity of 94%, specificity of 68%). Postoperative early morning cortisol levels seem to be less sensitive and specific 
in predicting long-term corticotroph function than measurements after 6 weeks and 1 year, emphasizing the importance of 
endocrine follow-up testing.
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Introduction
Tumors of the pituitary gland account for approximately 15% 
of all intracranial tumors and the benign pituitary adenoma 
represent the most common encountered entity (up to 85%) 
[8, 39, 42, 43] of all sellar lesions. The transnasal trans-
sphenoidal (TSS) operative resection of sellar tumors has 
firstly been described in 1907 by Schlofer et al. and further 
developed by Cushing et al. in 1909 [5, 27, 40]. Nowadays, 
TSS is considered the most appropriate and initial approach 
for treatment of tumors of the pituitary gland [40, 41]. It 
can reduce hospital costs by shortening the length of hos-
pital stay (LOH) and presents a safe and effective surgical 
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resection option with fewer complications and better clinical 
out-comes than the transcranial route [44, 45].
Pituitary adenoma patients may present with mass effect 
and lead to a compression of the optic chiasm with visual 
field defects and impaired visual acuity. As the pituitary 
gland plays a pivotal role in hormone regulation, adenomas 
can lead to an impaired adrenal pituitary function or hor-
mone hypersecretion such as Acromegaly or M. Cushing due 
to a hypersecretion of growth hormone (GH) or adrenocor-
ticotropic hormone (ACTH).
Most important is the preservation of an intact hypotha-
lamic–pituitary–adrenal-axis (HPA) regulating in a circa-
dian rhythm and depending on physical stress levels cortisol 
release through the stimulation of ACTH [15]. Therefore, 
patients need to be monitored closely for symptoms of 
hypocortisolism, the most dangerous and life-threatening 
complication of pituitary deficiency [28], presenting with 
impaired metabolism such as anorexia, fatigue, hypotension 
and nausea, and potentially leading to the lethal adrenal cri-
sis including shock and volume depletion called Addison’s 
crisis [18, 33]. Many studies have focused on the optimal 
serum cortisol threshold (or cut-off value) to determine 
whether a patient suffers from hypocortisolism or not, and 
to prevent patients from adrenal corticotropic deficiency by 
substituting hydrocortisone [3, 17, 29, 31, 43]. Oral hydro-
cortisone, the generic pharmaceutical name of cortisol, has 
a plasma half-life of 1.5 h, a biologic half-life of 8–12 h, and 
a glucocorticoid potency of 0.8 [13, 36]. Minimum serum 
values range from 4 to 20 μg/dl (morning serum level, 1 µg/
dl = 27,59 nmol/l), but only few conducted studies have been 
performed and published with a long enough follow-up to 
establish cortisol supplementation criteria [24, 28, 43].
The optimal cut-off value of morning fasting cortisol level 
plays a pivotal role in determining the risk for hypocorti-
solism and needs to be detected early in order to start the 
optimal treatment, but also to avoid hydrocortisone over-
replacement to minimize possible side effects like osteo-
porosis and impaired glucose tolerance [2, 37]. Regular 
follow-up testing of the fasting morning cortisol levels is 
therefore performed before and after surgery, as well as at 
neurooncological follow-up appointments.
In our study, we focus on the diagnostic value of direct 
postoperative and follow-up cortisol measurements and 
possible influencing prognostic factors to detect pituitary 
hypocortisolism due to surgery-related injury of the pituitary 
gland, in order to provide the most reliable timing and corti-
sol cut-off value to predict long-term need of hydrocortisone 
replacement therapy.
Methods
We retrospectively analyzed all patients treated via TSS for 
histologically proven pituitary adenomas from April 2006 to 
January 2019 in our neurosurgical department in a tertiary 
referral hospital by two senior attending neurosurgeons.
Inclusion criteria were diagnosed hormone-inactive ade-
noma of the sellar region, complete data available including 
complete clinical and endocrinological data such as cortisol 
serum levels, age > 18 years, minimum endocrinological and 
clinical follow-up of 1 year after surgery, and surgery per-
formed via a transsphenoidal approach. Patients with other 
tumors than adenoma of the sellar region and prior intake 
of prednisolone were excluded from our study. Patients pre-
senting with pituitary apoplexy were included if complete 
endocrinological testing was performed before surgery 
and adenoma tissue was identified in the specimens sent to 
histopathology.
We retrieved demographic factors from our archives such 
as gender, age, and Karnosfky performance scale (KPS), 
as well as comorbidities from patient files, pre- and post-
operative imaging (magnetic resonance imaging MRI, 
computed tomography CT) for extent of resection (EOR, 
gross total resection GTR vs. partial resection (PR)), 
and perioperative hormone levels of basal cortisol (µg/
dl) gained from the patient in the morning (fasting serum 
values, cobas 8000 analyzer Roche). Urinary free cortisol 
levels were not included for analysis. Information on the 
operation performed included microscopic vs. endoscopic 
approach, length of operation (mean time in minutes), and 
intra-operative complications (cerebrospinal fluid CSF leak, 
major bleeding). The minimum clinical and endocrinologi-
cal follow-up time was 1 year, and patients were monitored 
for anterior and posterior pituitary deficiency and need for 
hormone substitution after TSS. Corticotropic deficiency 
was also diagnosed when the patient presented with clinical 
symptoms of hypocortisolism after withdrawing or reduc-
ing the oral hydrocortisone substitution, even if the basal 
morning serum cortisol level was above a defined threshold.
Statistical correlation analyzes were performed using 
the IBM SPSS software (Version 26.0.0.0). Multivariable 
analyses were conducted using ANOVA and  Chi2 testing. 
Cut-off values were determined using the receiver-operator 
curve (ROC), area under the curve (AUC), and the Youden-
Index [46]. Correlation analysis was performed using the 
Spearman coefficient, and a p-value < 0.05 was considered 
significant.
The presented study meets the ethical standards outlined 
in the Declaration of Helsinki, ethics approval was obtained 
before performing the analysis (Ethikkommission der Tech-
nischen Universität München, Prof. Dr. Schmidt), and the 
positive vote was registered under the number 231/20-S. Due 
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to the retrospective nature of the study, informed consent 
was waived in accordance with the Ethics Commission. All 




We were able to identify 429 patients who were treated via 
the transsphenoidal approach for tumors of the sellar and 
parasellar region from April 2006 to January 2019 in our 
clinical neurosurgical department. Sixty-two patients with 
hormone-producing adenoma causing Acromegaly and M. 
Cushing were excluded due to their distinct preoperative cor-
tisol levels (Fig. 1). Fifty-nine patients were excluded due 
to histopathological diagnosis of tumors other than pituitary 
adenoma (meningioma, Rathke’s cleft cysts, hypophysitis) 
due to their distinct clinical outcome. In total, 97 patients 
were lost to follow-up endocrinological data at 1 year.
We were able to include 211 patients for further analy-
sis. Comparing the numbers over the years, we observed a 
trend towards increasing numbers of surgeries performed 
for transnasal pituitary adenoma resection (number of cases 
included between 2006 and 2012, n = 72; 2013–2019, 139 
cases).
Median age was 56 years with a range of 20–86 years. 
Sixty percent (n = 127) were male and 40% (n = 84) 
female patients. Median preoperative KPS was 90% (range 
Fig. 1  Flowchart describing the 
number of patients meeting the 
inclusion and exclusion criteria 
and showing the number of 




20–100%). 97.6% of the patients suffered from pituitary 
macroadenoma, and only 5 patients presented with pro-
gressive hormone-inactive pituitary microadenoma (only 
selected cases such as patients presenting with tumor growth 
on follow-up imaging leading to the indication of surgical 
removal (2.4%)).
Hormone levels
All patients were given intra- and postoperative hydro-
cortisone substitution according to the following standard 
scheme: patients obtained 50 mg of intravenous hydrocor-
tisone injection on induction, followed by immediate initia-
tion of a continuous infusion of hydrocortisone 100 mg/24 h. 
On postoperative day 1, patients obtained 80 mg (infusion 
for 24 h). On day 2 after surgery, we continued with an 
oral administration of 60 mg hydrocortisone (20 mg in the 
morning, noon, and evening) with continuous reduction of 
10 mg per day until the maintenance dosage of 20 mg per 
day (10 mg in the morning and at noon).
Table 1 describes the preoperative values, postopera-
tive values, and long-term cortisol results after one year 
of patients grouped by hypocortisolism. Mean preopera-
tive early morning cortisol level was 11.7 µg/dl (range 0.2 
to 37.1 μg/dl) and mean postoperative (5 days after TSS) 
level was 12.6 µg/dl (range 0.2 to 45.1 μg/dl). At 6 weeks to 
12 weeks, mean early morning cortisol level was 11.9 µg/
dl (range 0.1 to 59.8 µg/dl) and long-term data (minimum 
1-year follow-up) revealed a mean basal cortisol level of 
11.2 µg/dl (range 0.1–35.1 µg/dl).
If grouped by clinical hypocortisolism symptoms and 
need for hydrocortisone substitution, mean basal serum cor-
tisol values in patients with hypocortisolism were 3.99 µg/
dl and 15.1 µg/dl. Mean hormone levels of basal cortisol at 
long-term follow-up (minimum 1 year) were 6.01 µg/dl for 
patients with long-term need of hydrocortisone substitution 
and 13.7 µg/dl for the healthy counterpart without replace-
ment therapy (Figs. 2 and 3, Table 1).
Clinical and surgical outcome
The overall clinical outcome showed satisfying postop-
erative results. Median postoperative KPS of our patients 
was 90% (range 40–100%). Mean duration of surgery was 
Table 1  Preoperative hormone levels classified by timing of the anal-
ysis and classified in patients with corticotroph deficiency and intact 
corticotroph function 5 days after surgery (“early postoperative”), 6 to 
12 weeks after surgery and 1 year after surgery with 95% CI (confi-
dence interval)
Mean hormone level Preoperative Early postoperative After 6–12 weeks 1 year after surgery
























Fig. 2  Distribution of basal 
cortisol levels depending on 
necessity of hydrocortisone 
substitution (0: no substitution, 
1: hydrocortisone substitution) 
before surgery (in µg/dl)
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84 min, ranging from 24 to 489 min. Of all performed sur-
geries, 68.1% of the TSS were performed with a microscope, 
and in 31.9% of the cases with a 0° or 30° endoscope. We 
did not identify any significant differences in terms of com-
plications or clinical outcome between patients operated 
with the endoscope or microscopical approach.
Overall, perioperative complications occurred in 18% of 
the operated cases (occurrence of transient diabetes insipi-
dus with the need for desmopressin substitution in 7.1%, 
occurrence of an intraoperative dural tear with the need for 
postoperative surgical revision in 4.7%, operative revision 
due to postoperative hemorrhage in three cases 1.4%).
GTR was achieved in 79.1% (evaluated by analyzing the 
postoperative imaging and determined as no residual tumor 
detected on the postoperative MRI). Patients with residual 
(mostly suprasellar) tumor were advised to perform a follow-
up MRI after 6–12 weeks. In cases with good access to the 
descended residual tumor, the patients underwent a second 
transnasal surgery.
Cut‑off values, sensitivity and specificity
According to the receiver operator characteristic (ROC) 
curves, fasting serum cortisol levels analyzed 6 weeks to 
3 months after surgery were more accurate in predicting 
long-term intact corticotroph function (area under the curve, 
AUC 0.808) compared to the directly postoperative assessed 
levels (AUC 0.740). Naturally, the AUC of long-term basal 
cortisol levels predicted the corticotroph function most 
appropriately (AUC 0.864) (Fig. 4).
The cut-off value for direct postoperative fasting serum 
cortisol level was 6.9 µg/dl (sensitivity 86.4%, specificity 
56%, Youden-Index 0.424). For values measured after 6 to 
12 weeks after surgery, the cut-off prognostic basal cortisol 
was 6.95 µg/dl with a sensibility of 94.1% and specificity of 
68% (Youden-Index 0.621). Basal cortisol measured after at 
least one year after surgery had the highest prognostic power 
at a value of 8.35 µg/dl (sensitivity 90%, specificity 82%, 
Youden-Index 0.718) (Table 2).
Fig. 3  Distribution of basal 
cortisol levels depending on 
necessity of hydrocortisone 
substitution (0: no substitution, 
1: hydrocortisone substitution) 
1 year after surgery (in µg/dl)
Fig. 4  Receiver operator characteristic (ROC) curve showing the 
sensitivity and specificity of direct postoperative basal cortisol level, 
3 months postoperatively and long-term, indicating a higher sensibil-





Long-term hydrocortisone replacement after 1  year 
was observed in 30.9% of the patients and in 30.4% 
of the patients before surgical treatment. Overall, 9% 
recovered from preoperative hypocortisolism and 10.4% 
developed a new postoperative impaired HPA-axis lead-
ing to hypocortisolism. In total, 80.6% of our patients 
had no changes regarding the pituitary function (persis-
tent hypocortisolism without recovery or intact func-
tion postoperatively in patients without preoperative 
hypocortisolism).
In 14.6%, the postoperative cortisol level was above the 
measured threshold of 6.9 µg/dl while patients still suffered 
from long-term hypocortisolism (false negative patients). 
False positive results occurred in 11.1% of the cases with 
our assessed direct postoperative cortisol cut-off value of 
6.9 µg/dl (hydrocortisone substitution in patients with poten-
tially intact HPA-axis). In total, regarding that all patients 
had a hydrocortisone replacement for safety reasons until 
the first endocrinological follow-up 6 weeks to 3 months 
after surgery, 66.3% of the patients underwent substitution 
while having a basal postoperative cortisol level above the 
determined threshold.
Prognostic factors
Gender, age, year of operation, GTR, and preoperative 
KPS did not significantly influence the occurrence of a new 
postoperative hypocortisolism (p > 0.05). The occurrence 
of complications significantly increased the risk for a new 
postoperative corticotroph deficiency (r, 0.281; p < 0.01, OR 
4.4, overall long-term hypocortisolism OR 2.7, p 0.006) and 
the postoperative clinical outcome in terms of KPS (KPS, 
r, − 0.165; p 0.018).
Discussion
Compared to current literature, a new onset of hypocorti-
solism is described in approximately 2% up to 10% [4, 9, 
11, 23, 35], depending on the surgical approach which is 
consistent with our presented results.
Long-term hypocortisolism requiring substitution with 
hydrocortisone occurred in 30.9% of all cases; in 10.4%, the 
deficiency was new, and 9% of the patients with preoperative 
hypocortisolism had intact pituitary hormone secretion at 
follow-up of minimum 1 year.
Our results show a higher rate of postoperative improve-
ment of preoperative manifest hypocortisolism, as current 
literature reports of a laboratory normalization of 3% after 
6 months for the cortisol axis. We also identified a higher 
rate of new hypocortisolism compared to the stated 6% 
of new postoperative hypocortisolism in current literature 
[20]. Compared to other tumors of the sellar regions, these 
percentages seem very low (craniopharyngiomas: up to 
53% of postoperative hypocortisolism after TSS [26], and 
rate of hypocortisolism after resection of Rathke’s cleft 
cyst, 24% [25]). As these tumors were excluded from the 
analysis, no comparison between current literature and our 
Table 2  Morning serum cortisol 
levels assessed on the fifth day 
after surgery (postoperative 
value), 6–12 weeks after surgery 
and one year after surgery
The optimum cut-off value is marked*. The lower and higher cortisol value describes the 95% sensitivity 
and 95% specificity. The Youden index describes the maximum potential effectiveness of a certain cut-off 
value. Note that the described cut-off value determines the intact corticotropic function
Numbers in boldface determine the highest sensitivity or specificity
Cortisol morning serum 
values (ug/dl)
Normal pituitary function if 
cortisol greater than or equal 
 toa
Sensitivity Specificity Youden Index
Postoperative value 2.8 0.949 0.32 0.269
6.9* 0.864 0.56 0.424
10.15 0.729 0.64 0.369
20.65 0.195 0.94 0.135
6–12 weeks after surgery 6.85 0.949 0.66 0.609
6.95* 0.941 0.68 0.621
10.05 0.746 0.78 0.526
20.3 0.085 0.94 0.025
1 year after surgery 7.05 0.949 0.72 0.669
8.35* 0.898 0.82 0.718
10.05 0.805 0.84 0.645
20.45 0.076 0.94 0.016
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results can be made concerning other sellar tumors than 
pituitary adenoma.
Limitations
Our study analyzed patients retrospectively, but complete 
long-term follow up data was available for a considerably 
large series of 211 patients. Unfortunately, the burden of 
disease caused by long-term hormone substitution has not 
been evaluated yet and was not included in our data exami-
nation. Symptoms of hypocortisolism, such as fatigue and 
impairment of daily living activities [14], are therefore not 
stated or described in our study. Therefore, we cannot assess 
the overall burden of disease caused by the transnasal surgi-
cal resection of pituitary adenoma. We unfortunately did 
not evaluate the subjective disability experienced and the 
prospective assessment of quality of life and impairment 
of daily living activities would give beneficial information 
on the overall treatment benefit or risks for patients treated 
surgically for pituitary adenoma [14].
Furthermore, patients were only included and analyzed, 
if complete endocrinological and clinical follow-up data was 
available. A bias is therefore included and needs to be dis-
cussed, potentially including more patients with complica-
tions and postoperative deficiencies in the analysis because 
of their increased need of postoperative supervision and 
follow-up appointments. Therefore, the evaluated 10% rate 
of new postoperative hypocortisolism is most probably over-
rated in our patient cohort.
As we aimed to focus on hypocortisolism, we did not 
assess other pituitary deficiencies such as the often-fre-
quented hypogonadism in male patients which presents a 
limitation of our study.
We performed a purely retrospective analysis, and 
patients describing symptoms of hypocortisolism after 
hydrocortisone withdrawal were continued on hydrocorti-
sone substitution without further assessment, based on the 
assumption that ACTH testing may not detect cases of new-
onset secondary adrenal insufficiency [7, 10]. The uncer-
tainty around the clinical and the laboratory investigation 
of hypocortisolism remains a strong limitation of our study.
Cut‑off values and timing of analysis
While detection of intact corticotroph function is of main 
interest to prevent Addison’s crisis, we found different val-
ues for the sensitivity and specificity of laboratory cortisol 
testing direct postoperatively, 6–12 weeks after surgical 
treatment and 1 year after surgery. Of course, the closer the 
laboratory analysis coincides with the long-term follow-
up clinical examination, the more sensitive and specific 
it becomes as some patients recover from postoperative 
hormone deficiencies and some patients tend to develop a 
secondary hypocortisolism. Our main interest is therefore to 
question the use of direct postoperative basal cortisol assess-
ment if its use is very limited.
Prediction of long‑term corticotropic deficiency
The exact cut-off value of cortisol serum levels to deter-
mine hypocortisolism and its appropriate timing of testing 
(laboratory value measured in µg/dl in morning serum) is 
still matter of debate [6, 24, 38]. Published cut-off values 
range between 4 µg/dl [21], 8 µg/dl [6], and 14 µg/dl [21]. 
In our study, we classified patients based on their actual 
clinical need of hydrocortisone substitution regardless of 
their serum cortisol levels, which may over- or underes-
timate the real fraction of patients suffering from hypo-
cortisolism due to false interpretation symptoms such as 
fatigue. The measured and assessed cortisol cut-off value 
of 8.35 µg/dl is congruent with and within the range of 
published data. Patients with basal serum cortisol levels 
above > 10 µg/dl were declared as “ hypocortisolism” if 
they still presented with symptoms of hypocortisolism 
and had the clinical need for hydrocortisone supplementa-
tion when the hydrocortisone administration was reduced 
(mostly symptoms of fatigue). False high basal cortisol 
levels due to either ingestion of hydrocortisone before 
blood testing (24 h off replacement hydrocortisone) or 
even factitious ingestion of hydrocortisone [1] were tried 
to be accounted for but cannot be excluded completely and 
may increase the uncertainty around a specific “cut-off” 
value for intact corticotroph function. Values from patients 
stating they had their hydrocortisone medication or food/ 
coffee intake before the blood was taken were of course 
excluded from analysis.
In our department, hydrocortisone supplementation is 
usually continued for 6 to 12 weeks after transsphenoidal 
surgery until the following endocrine laboratory testing, 
regardless of the assessed postoperative cortisol serum val-
ues. Side effects of supplementary (unnecessary) hydrocorti-
sone administration could be prevented if the post-operative 
basal cortisol level or timing was more reliable and as early 
as possible, and direct postoperative testing obsolete if the 
positive predictive value is inferior to the long-term testing. 
Unfortunately, we did not assess possible consequences of 
supplementary (over-substituted) hydrocortisone substitu-
tion in terms of possible side effects such as high blood pres-
sure, diabetic complications, or osteoporosis [36]. In order to 
assess the complete impact of false hydrocortisone admin-
istration, a prospective analysis of patients suffering from 
pituitary adenoma would be necessary, with a close attention 
to signs of under- or over-supplementation. Neither did we 
assess economic differences in term of cost-effectiveness of 




In total 66.3% if the patients underwent hydrocortisone 
substitution (substitution dosage of 10 mg administered in 
the morning and midday for 6 weeks) while having intact 
postoperative pituitary function using our defined cut-off 
value. The use of direct postoperative cortisol level evalua-
tion has previously been questioned regarding its utility in 
clinical practice and implication for further hydrocortisone 
substitution [16, 19, 30, 32]. With the risk of Addison’s dis-
ease, some patient may be rather over-supplemented, with 
the risk of long-term effects of hypercortisolism [34]. There-
fore, reliable cut-off values with a high positive predictive 
value and an optimal timing of analysis need to be provided. 
In out department, we shifted towards a more individual 
approach focusing on patients with very low postoperative 
cortisol levels and higher levels to present in our outpatient 
department earlier in order to adjust or stop the hydrocorti-
sone substitution. We furthermore abandoned the strict cor-
tisol cut-off value of 10ug/dl and focus more on the clinical 
and functional status of the patient after with-drawing the 
hydrocortisone substitution. Nevertheless, the higher mortal-
ity caused by hypocortisolism [12] compared to risks caused 
by over-supplementation of hydrocortisone may shift the 
optimal early cut-off value for basal cortisol towards a higher 
sensibility at the cost of a lower specificity.
Hypocortisolism may be caused by surgery related injury 
of the pituitary gland, but also due to long-term administra-
tion of corticoids. In our cohort population, patients obtained 
only 20 mg of oral hydrocortisone per day, which is usually 
below the threshold causing HPA suppression [22]. Only 
one patient was given prednisolone for rheumatoid arthritis 
prior to pituitary surgery and was therefore excluded from 
the analysis.
Conclusion
In 30.9% of all patients, long-term hydrocortisone substitu-
tion was necessary to support the adrenocorticotropic axis 
in patients with hypocortisolism. Prediction of hormone 
production, especially hypocortisolism, remains an impor-
tant matter of debate in the neurooncological context; the 
duration of hydrocortisone substitution and timing of evalu-
ation should therefore be questioned. In our study, evaluated 
cut-off values were congruent with published literature, and 
substitution in patients with intact postoperative pituitary 
function should be discussed further to reduce the risk of 
potential side effects. An improvement in reliability and 
prognostic quality of laboratory testing may reduce hydro-
cortisone oversupply without increasing the amount of unde-
tected postoperative hypocortisolism.
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